Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
<p>TRAEs (reported as PTs) in ≥20% of patients, grade ≥3 TRAEs in ≥5% of patients, and AESIs in ≥10% of patients in the dose-expansion phase.</p>
में बचाया:
| मुख्य लेखक: | |
|---|---|
| अन्य लेखक: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| प्रकाशित: |
2025
|
| विषय: | |
| टैग: |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|
| _version_ | 1849927621960269824 |
|---|---|
| author | Kristoffer Staal Rohrberg (15009138) |
| author2 | Juanita S. Lopez (22687839) Mohammed M. Milhem (15352499) Christian U. Blank (14850778) Irene Reijers (22687842) Fiona Thistlethwaite (22687845) Ruth Plummer (15028641) Sarina A. Piha-Paul (15294428) Pasi A. Jänne (14954872) Elaine Shum (14955138) Heather M. Shaw (22687848) Philip R. Debruyne (20432881) Cristopher Lao (22687851) Jean-Francois Baurain (15031089) Jennifer H. Choe (15052775) Eelke Gort (17740951) Yujie Zhao (22687854) Guy Jerusalem (15017648) Patrick Schöffski (15013461) Andrew William Chen (22687857) Eric A. Cohen (15017996) Walter C. Mankowski (22687860) Leonid Roshkovan (22687863) Sharyn I. Katz (22687866) Despina Kontos (15018005) Lauren K. Brady (22687869) Mohammed Qutaish (22687872) Patricia Garrido Castro (22687875) Nora Pencheva (22687878) Gaurav Bajaj (22687881) Yali Fu (22687884) Kristian Windfeld (22687887) Panagiota Reiter (22687890) Maria Jure-Kunkel (15117740) Brandon W. Higgs (15035279) Katayoun I. Amiri (22687893) Tahamtan Ahmadi (22687896) Ulf Forssmann (22687899) Suresh S. Ramalingam (14951413) Ignace Vergote (15027870) |
| author2_role | author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| author_facet | Kristoffer Staal Rohrberg (15009138) Juanita S. Lopez (22687839) Mohammed M. Milhem (15352499) Christian U. Blank (14850778) Irene Reijers (22687842) Fiona Thistlethwaite (22687845) Ruth Plummer (15028641) Sarina A. Piha-Paul (15294428) Pasi A. Jänne (14954872) Elaine Shum (14955138) Heather M. Shaw (22687848) Philip R. Debruyne (20432881) Cristopher Lao (22687851) Jean-Francois Baurain (15031089) Jennifer H. Choe (15052775) Eelke Gort (17740951) Yujie Zhao (22687854) Guy Jerusalem (15017648) Patrick Schöffski (15013461) Andrew William Chen (22687857) Eric A. Cohen (15017996) Walter C. Mankowski (22687860) Leonid Roshkovan (22687863) Sharyn I. Katz (22687866) Despina Kontos (15018005) Lauren K. Brady (22687869) Mohammed Qutaish (22687872) Patricia Garrido Castro (22687875) Nora Pencheva (22687878) Gaurav Bajaj (22687881) Yali Fu (22687884) Kristian Windfeld (22687887) Panagiota Reiter (22687890) Maria Jure-Kunkel (15117740) Brandon W. Higgs (15035279) Katayoun I. Amiri (22687893) Tahamtan Ahmadi (22687896) Ulf Forssmann (22687899) Suresh S. Ramalingam (14951413) Ignace Vergote (15027870) |
| author_role | author |
| dc.creator.none.fl_str_mv | Kristoffer Staal Rohrberg (15009138) Juanita S. Lopez (22687839) Mohammed M. Milhem (15352499) Christian U. Blank (14850778) Irene Reijers (22687842) Fiona Thistlethwaite (22687845) Ruth Plummer (15028641) Sarina A. Piha-Paul (15294428) Pasi A. Jänne (14954872) Elaine Shum (14955138) Heather M. Shaw (22687848) Philip R. Debruyne (20432881) Cristopher Lao (22687851) Jean-Francois Baurain (15031089) Jennifer H. Choe (15052775) Eelke Gort (17740951) Yujie Zhao (22687854) Guy Jerusalem (15017648) Patrick Schöffski (15013461) Andrew William Chen (22687857) Eric A. Cohen (15017996) Walter C. Mankowski (22687860) Leonid Roshkovan (22687863) Sharyn I. Katz (22687866) Despina Kontos (15018005) Lauren K. Brady (22687869) Mohammed Qutaish (22687872) Patricia Garrido Castro (22687875) Nora Pencheva (22687878) Gaurav Bajaj (22687881) Yali Fu (22687884) Kristian Windfeld (22687887) Panagiota Reiter (22687890) Maria Jure-Kunkel (15117740) Brandon W. Higgs (15035279) Katayoun I. Amiri (22687893) Tahamtan Ahmadi (22687896) Ulf Forssmann (22687899) Suresh S. Ramalingam (14951413) Ignace Vergote (15027870) |
| dc.date.none.fl_str_mv | 2025-11-26T07:40:19Z |
| dc.identifier.none.fl_str_mv | 10.1158/2767-9764.30719268 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Table_3_from_Phase_I_II_Study_of_AXL-Specific_Antibody_Drug_Conjugate_Enapotamab_Vedotin_in_Patients_with_Advanced_Solid_Tumors/30719268 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunology Antibodies/immunoconjugates Lung Cancer Melanoma Ovarian Cancer Sarcomas |
| dc.title.none.fl_str_mv | Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | <p>TRAEs (reported as PTs) in ≥20% of patients, grade ≥3 TRAEs in ≥5% of patients, and AESIs in ≥10% of patients in the dose-expansion phase.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_da83453fa7e11cbe1b1d8849facc2fd9 |
| identifier_str_mv | 10.1158/2767-9764.30719268 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30719268 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid TumorsKristoffer Staal Rohrberg (15009138)Juanita S. Lopez (22687839)Mohammed M. Milhem (15352499)Christian U. Blank (14850778)Irene Reijers (22687842)Fiona Thistlethwaite (22687845)Ruth Plummer (15028641)Sarina A. Piha-Paul (15294428)Pasi A. Jänne (14954872)Elaine Shum (14955138)Heather M. Shaw (22687848)Philip R. Debruyne (20432881)Cristopher Lao (22687851)Jean-Francois Baurain (15031089)Jennifer H. Choe (15052775)Eelke Gort (17740951)Yujie Zhao (22687854)Guy Jerusalem (15017648)Patrick Schöffski (15013461)Andrew William Chen (22687857)Eric A. Cohen (15017996)Walter C. Mankowski (22687860)Leonid Roshkovan (22687863)Sharyn I. Katz (22687866)Despina Kontos (15018005)Lauren K. Brady (22687869)Mohammed Qutaish (22687872)Patricia Garrido Castro (22687875)Nora Pencheva (22687878)Gaurav Bajaj (22687881)Yali Fu (22687884)Kristian Windfeld (22687887)Panagiota Reiter (22687890)Maria Jure-Kunkel (15117740)Brandon W. Higgs (15035279)Katayoun I. Amiri (22687893)Tahamtan Ahmadi (22687896)Ulf Forssmann (22687899)Suresh S. Ramalingam (14951413)Ignace Vergote (15027870)CancerImmuno-oncologyClinical Research and TrialsClinical Trial ResultsImmunologyAntibodies/immunoconjugatesLung CancerMelanomaOvarian CancerSarcomas<p>TRAEs (reported as PTs) in ≥20% of patients, grade ≥3 TRAEs in ≥5% of patients, and AESIs in ≥10% of patients in the dose-expansion phase.</p>2025-11-26T07:40:19ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.1158/2767-9764.30719268https://figshare.com/articles/dataset/Table_3_from_Phase_I_II_Study_of_AXL-Specific_Antibody_Drug_Conjugate_Enapotamab_Vedotin_in_Patients_with_Advanced_Solid_Tumors/30719268CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307192682025-11-26T07:40:19Z |
| spellingShingle | Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors Kristoffer Staal Rohrberg (15009138) Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunology Antibodies/immunoconjugates Lung Cancer Melanoma Ovarian Cancer Sarcomas |
| status_str | publishedVersion |
| title | Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors |
| title_full | Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors |
| title_fullStr | Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors |
| title_full_unstemmed | Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors |
| title_short | Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors |
| title_sort | Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors |
| topic | Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunology Antibodies/immunoconjugates Lung Cancer Melanoma Ovarian Cancer Sarcomas |